Literature DB >> 24554772

Cholesterol crystals induce complement-dependent inflammasome activation and cytokine release.

Eivind O Samstad1, Nathalie Niyonzima, Stig Nymo, Marie H Aune, Liv Ryan, Siril S Bakke, Knut T Lappegård, Ole-Lars Brekke, John D Lambris, Jan K Damås, Eicke Latz, Tom E Mollnes, Terje Espevik.   

Abstract

Inflammation is associated with development of atherosclerosis, and cholesterol crystals (CC) have long been recognized as a hallmark of atherosclerotic lesions. CC appear early in the atheroma development and trigger inflammation by NLRP3 inflammasome activation. In this study we hypothesized whether CC employ the complement system to activate inflammasome/caspase-1, leading to release of mature IL-1β, and whether complement activation regulates CC-induced cytokine production. In this study we describe that CC activated both the classical and alternative complement pathways, and C1q was found to be crucial for the activation. CC employed C5a in the release of a number of cytokines in whole blood, including IL-1β and TNF. CC induced minimal amounts of cytokines in C5-deficient whole blood, until reconstituted with C5. Furthermore, C5a and TNF in combination acted as a potent primer for CC-induced IL-1β release by increasing IL-1β transcripts. CC-induced complement activation resulted in upregulation of complement receptor 3 (CD11b/CD18), leading to phagocytosis of CC. Also, CC mounted a complement-dependent production of reactive oxygen species and active caspase-1. We conclude that CC employ the complement system to induce cytokines and activate the inflammasome/caspase-1 by regulating several cellular responses in human monocytes. In light of this, complement inhibition might be an interesting therapeutic approach for treatment of atherosclerosis.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24554772      PMCID: PMC3985066          DOI: 10.4049/jimmunol.1302484

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  41 in total

Review 1.  Beyond lysis: how complement influences cell fate.

Authors:  Duncan S Cole; B Paul Morgan
Journal:  Clin Sci (Lond)       Date:  2003-05       Impact factor: 6.124

2.  Expression and function of the C5a receptor in rat alveolar epithelial cells.

Authors:  Niels C Riedemann; Ren-Feng Guo; Vidya J Sarma; Ines J Laudes; Markus Huber-Lang; Roscoe L Warner; Eric A Albrecht; Cecilia L Speyer; Peter A Ward
Journal:  J Immunol       Date:  2002-02-15       Impact factor: 5.422

Review 3.  Complement membrane attack on nucleated cells: resistance, recovery and non-lethal effects.

Authors:  B P Morgan
Journal:  Biochem J       Date:  1989-11-15       Impact factor: 3.857

4.  George Lyman Duff memorial lecture. Progression and regression of atherosclerotic lesions. Insights from lipid physical biochemistry.

Authors:  D M Small
Journal:  Arteriosclerosis       Date:  1988 Mar-Apr

5.  Recombinant C5a stimulates transcription rather than translation of interleukin-1 (IL-1) and tumor necrosis factor: translational signal provided by lipopolysaccharide or IL-1 itself.

Authors:  R Schindler; J A Gelfand; C A Dinarello
Journal:  Blood       Date:  1990-10-15       Impact factor: 22.113

6.  Mechanisms of complement activation by crystalline cholesterol.

Authors:  W Vogt; I von Zabern; B Damerau; D Hesse; B Lühmann; R Nolte
Journal:  Mol Immunol       Date:  1985-02       Impact factor: 4.407

7.  Generation of complement anaphylatoxins and C5b-9 by crystalline cholesterol oxidation derivatives depends on hydroxyl group number and position.

Authors:  P S Seifert; M D Kazatchkine
Journal:  Mol Immunol       Date:  1987-12       Impact factor: 4.407

8.  Cholesterol and atheroma lipids activate complement and stimulate granulocytes. A possible mechanism for amplification of ischemic injury in atherosclerotic states.

Authors:  D E Hammerschmidt; C S Greenberg; O Yamada; P R Craddock; H S Jacob
Journal:  J Lab Clin Med       Date:  1981-07

9.  C5a stimulates secretion of tumor necrosis factor from human mononuclear cells in vitro. Comparison with secretion of interleukin 1 beta and interleukin 1 alpha.

Authors:  S Okusawa; K B Yancey; J W van der Meer; S Endres; G Lonnemann; K Hefter; M M Frank; J F Burke; C A Dinarello; J A Gelfand
Journal:  J Exp Med       Date:  1988-07-01       Impact factor: 14.307

10.  CD36 coordinates NLRP3 inflammasome activation by facilitating intracellular nucleation of soluble ligands into particulate ligands in sterile inflammation.

Authors:  Frederick J Sheedy; Alena Grebe; Katey J Rayner; Parisa Kalantari; Bhama Ramkhelawon; Susan B Carpenter; Christine E Becker; Hasini N Ediriweera; Adam E Mullick; Douglas T Golenbock; Lynda M Stuart; Eicke Latz; Katherine A Fitzgerald; Kathryn J Moore
Journal:  Nat Immunol       Date:  2013-06-30       Impact factor: 25.606

View more
  100 in total

Review 1.  Complementing the inflammasome.

Authors:  Martha Triantafilou; Timothy R Hughes; Bryan Paul Morgan; Kathy Triantafilou
Journal:  Immunology       Date:  2016-02       Impact factor: 7.397

Review 2.  Drivers of age-related inflammation and strategies for healthspan extension.

Authors:  Emily L Goldberg; Vishwa Deep Dixit
Journal:  Immunol Rev       Date:  2015-05       Impact factor: 12.988

3.  Eculizumab treatment and impaired opsonophagocytic killing of meningococci by whole blood from immunized adults.

Authors:  Monica Konar; Dan M Granoff
Journal:  Blood       Date:  2017-06-19       Impact factor: 22.113

Review 4.  Molecular regulation of cell fate in cerebral ischemia: role of the inflammasome and connected pathways.

Authors:  George Trendelenburg
Journal:  J Cereb Blood Flow Metab       Date:  2014-09-17       Impact factor: 6.200

5.  Luteolin alleviates NLRP3 inflammasome activation and directs macrophage polarization in lipopolysaccharide-stimulated RAW264.7 cells.

Authors:  Bu-Chun Zhang; Zhi Li; Wu Xu; Chu-Han Xiang; Yan-Feng Ma
Journal:  Am J Transl Res       Date:  2018-01-15       Impact factor: 4.060

6.  Cyclodextrin promotes atherosclerosis regression via macrophage reprogramming.

Authors:  Sebastian Zimmer; Alena Grebe; Siril S Bakke; Niklas Bode; Bente Halvorsen; Thomas Ulas; Mona Skjelland; Dominic De Nardo; Larisa I Labzin; Anja Kerksiek; Chris Hempel; Michael T Heneka; Victoria Hawxhurst; Michael L Fitzgerald; Jonel Trebicka; Ingemar Björkhem; Jan-Åke Gustafsson; Marit Westerterp; Alan R Tall; Samuel D Wright; Terje Espevik; Joachim L Schultze; Georg Nickenig; Dieter Lütjohann; Eicke Latz
Journal:  Sci Transl Med       Date:  2016-04-06       Impact factor: 17.956

Review 7.  The Intracellular Cholesterol Landscape: Dynamic Integrator of the Immune Response.

Authors:  Michael B Fessler
Journal:  Trends Immunol       Date:  2016-09-28       Impact factor: 16.687

Review 8.  The inflammasome and lupus: another innate immune mechanism contributing to disease pathogenesis?

Authors:  J Michelle Kahlenberg; Mariana J Kaplan
Journal:  Curr Opin Rheumatol       Date:  2014-09       Impact factor: 5.006

9.  A Fluorescent Reporter Mouse for Inflammasome Assembly Demonstrates an Important Role for Cell-Bound and Free ASC Specks during In Vivo Infection.

Authors:  Te-Chen Tzeng; Stefan Schattgen; Brian Monks; Donghai Wang; Anna Cerny; Eicke Latz; Katherine Fitzgerald; Douglas T Golenbock
Journal:  Cell Rep       Date:  2016-06-23       Impact factor: 9.423

Review 10.  Inflammasomes: a preclinical assessment of targeting in atherosclerosis.

Authors:  Jeremiah Stitham; Astrid Rodriguez-Velez; Xiangyu Zhang; Se-Jin Jeong; Babak Razani
Journal:  Expert Opin Ther Targets       Date:  2020-08-06       Impact factor: 6.902

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.